Publications

Peer-Reviewed Original Research Articles:

Dunbar AJ, Bowman RL, Park YC, O'Connor K, Izzo F, Myers RM, Karzai A, Zaroogian Z, Kim WJ, Fernández-Maestre I, Waarts MR, Nazir A, Xiao W, Codilupi T, Brodsky M, Farina M, Cai L, Cai SF, Wang B, An W, Yang JL, Mowla S, Eisman SE, Hanasoge Somasundara AV, Glass JL, Mishra T, Houston R, Guzzardi E, Martinez Benitez AR, Viny AD, Koche RP, Meyer SC, Landau DA, Levine RL. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer Discov. 2024 May 1;14(5):737-751. doi: 10.1158/2159-8290.CD-22-0952. PMID: 38230747; PMCID: PMC11061606.

Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, Park Y, Karzai A, Xiao W, Zaroogian Z, O'Connor K, Mowla S, Gobbo F, Verachi P, Martelli F, Sarli G, Xia L, Elmansy N, Kleppe M, Chen Z, Xiao Y, McGovern E, Snyder J, Krishnan A, Hill C, Cordner K, Zouak A, Salama ME, Yohai J, Tucker E, Chen J, Zhou J, McConnell T, Migliaccio AR, Koche R, Rampal R, Fan R, Levine RL, Hoffman R. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023 May 18;141(20):2508-2519. doi: 10.1182/blood.2022015418. PMID: 36800567; PMCID: PMC10273167.

Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, Wills J, Kelly D, Farina M, Cordner KB, Park Y, Kishore S, Juluru K, Iyengar NM, Levine RL, Zehir A, Park W, Khorana AA, Soff GA, Mantha S. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood. 2021 Apr 15;137(15):2103-2113. doi: 10.1182/blood.2020007488. PMID: 33270827; PMCID: PMC8057259.

Fidler TP, Dunbar A, Kim E, Hardaway B, Pauli J, Xue C, Abramowicz S, Xiao T, O'Connor K, Sachs N, Wang N, Maegdefessel L, Levine R, Reilly M, Tall AR. Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis. Nat Cardiovasc Res. 2024 Jan;3(1):60-75. doi: 10.1038/s44161-023-00405-9. Epub 2024 Jan 11. PMID: 38362011; PMCID: PMC10868728.

Bowman RL, Dunbar AJ, Mishra T, Xiao W, Waarts MR, Maestre IF, Eisman SE, Cai L, Mowla S, Shah N, Youn A, Bennett L, Fontenard S, Gounder S, Gandhi A, Bowman M, O'Connor K, Zaroogian Z, Sánchez-Vela P, Martinez Benitez AR, Werewski M, Park Y, Csete IS, Krishnan A, Lee D, Boorady N, Potts CR, Jenkins MT, Cai SF, Carroll MP, Meyer SE, Miles LA, Ferrell PB Jr, Trowbridge JJ, Levine RL. In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy. Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. doi: 10.1016/j.ccell.2024.10.009. PMID: 39532065; PMCID: PMC11561369.

Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, Sotelo J, Potenski C, Mimitou EP, Stahl M, El Ghaity-Beckley S, Arandela J, Raviram R, Choi DC, Hoffman R, Chaligné R, Abdel-Wahab O, Smibert P, Ghobrial IM, Scandura JM, Marcellino B, Levine RL, Landau DA. Mapping genotypes to chromatin accessibility profiles in single cells. Nature. 2024 May;629(8014):1149-1157. doi: 10.1038/s41586-024-07388-y. Epub 2024 May 8. PMID: 38720070; PMCID: PMC11139586.

Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2024 Nov 19:blood.2024026388. doi: 10.1182/blood.2024026388. Epub ahead of print. PMID: 39561280.

Verachi P, Gobbo F, Martelli F, Martinelli A, Sarli G, Dunbar A, Levine RL, Hoffman R, Massucci MT, Brandolini L, Giorgio C, Allegretti M, Migliaccio AR. The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice. Front Oncol. 2022 Mar 22;12:853484. doi: 10.3389/fonc.2022.853484. PMID: 35392239; PMCID: PMC8982152.

Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L. Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica. 2020 Mar;105(3):e91-e94. doi: 10.3324/haematol.2018.203729. Epub 2019 Aug 14. PMID: 31413098; PMCID: PMC7049364.

Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar A, Stivala S, Brkic S, Albrecht C, Vokalova L, Yang JL, Buczak K, Ghosh N, Passweg JR, Rovo A, Angelillo-Scherrer A, Pankov D, Dirnhofer S, Levine RL, Koche R, Meyer SC. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable. Clin Cancer Res. 2024 Feb 1;30(3):586-599. doi: 10.1158/1078-0432.CCR-23-0163. PMID: 37992313; PMCID: PMC10831334.

Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, Um JS, Tanaka K, Cai W, Yoo S, Dunbar A, Park Y, McAvoy D, Hosszu KK, Levine RL, Boelens JJ, Lorenz IC, Brentjens RJ, Daniyan AF. Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. 2024 May 20;12(5):e009013. doi: 10.1136/jitc-2024-009013. PMID: 38772686; PMCID: PMC11110598.

Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563. PMID: 37871309; PMCID: PMC10827405.

Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M. Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6. PMID: 30523054; PMCID: PMC6601104.

Billon P, Nambiar TS, Hayward SB, Zafra MP, Schatoff EM, Oshima K, Dunbar A, Breinig M, Park YC, Ryu HS, Tschaharganeh DF, Levine RL, Baer R, Ferrando A, Dow LE, Ciccia A. Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. Cell Rep. 2020 Mar 10;30(10):3280-3295.e6. doi: 10.1016/j.celrep.2020.02.068. PMID: 32160537; PMCID: PMC7108696.

Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046. PMID: 36075392.

Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Sep;18(9):1248-1269. doi: 10.6004/jnccn.2020.0042. PMID: 32886902.

Bernardi S, Farina M, Zanaglio C, Cattina F, Polverelli N, Schieppati F, Re F, Foroni C, Malagola M, Dunbar AJ, Russo D. ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial. Case Rep Hematol. 2020 Jan 11;2020:2795656. doi: 10.1155/2020/2795656. PMID: 32148977; PMCID: PMC7057007.

Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, Famulare CA, Goldberg AD, Cai SF, Dunbar A, Epstein-Peterson Z, Menghrajani KN, Glass JL, Taylor J, Viny AD, Giralt SS, Gyurkocza B, Shaffer BC, Tamari R, Levine RL, Tallman MS, Stein EM. The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. Am J Hematol. 2021 May 1;96(5):E171-E175. doi: 10.1002/ajh.26146. Epub 2021 Mar 24. PMID: 33650111; PMCID: PMC8335797.

Farina M, Bernardi S, Polverelli N, D'Adda M, Malagola M, Bosio K, Re F, Almici C, Dunbar A, Levine RL, Russo D. Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells. 2021 Oct 15;10(10):2764. doi: 10.3390/cells10102764. PMID: 34685741; PMCID: PMC8534986.

Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol. 2023 Jan;98(1):79-89. doi: 10.1002/ajh.26757. Epub 2022 Oct 31. PMID: 36251406; PMCID: PMC10080561.

McCarter JGW, Nemirovsky D, Famulare CA, Farnoud N, Mohanty AS, Stone-Molloy ZS, Chervin J, Ball BJ, Epstein-Peterson ZD, Arcila ME, Stonestrom AJ, Dunbar A, Cai SF, Glass JL, Geyer MB, Rampal RK, Berman E, Abdel-Wahab OI, Stein EM, Tallman MS, Levine RL, Goldberg AD, Papaemmanuil E, Zhang Y, Roshal M, Derkach A, Xiao W. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv. 2023 Sep 12;7(17):5000-5013. doi: 10.1182/bloodadvances.2023009675. PMID: 37142255; PMCID: PMC10471939.

Pritchard JE, Pearce JE, Snoeren IAM, Fuchs SNR, Götz K, Peisker F, Wagner S, Benabid A, Lutterbach N, Klöker V, Nagai JS, Hannani MT, Galyga AK, Sistemich E, Banjanin B, Flosdorf N, Bindels E, Olschok K, Biaesch K, Chatain N, Bhagwat N, Dunbar A, Sarkis R, Naveiras O, Berres ML, Koschmieder S, Levine RL, Costa IG, Gleitz HFE, Kramann R, Schneider RK. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Cell Rep. 2024 Jan 23;43(1):113608. doi: 10.1016/j.celrep.2023.113608. Epub 2023 Dec 20. PMID: 38117649; PMCID: PMC10828549.

Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008 Dec 15;68(24):10349-57. doi: 10.1158/0008-5472.CAN-08-2754. PMID: 19074904; PMCID: PMC2668538.

Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009 Dec 20;27(36):6109-16. doi: 10.1200/JCO.2009.23.7503. Epub 2009 Nov 9. PMID: 19901108; PMCID: PMC3040009.

Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 2013 Jun;27(6):1301-9. doi: 10.1038/leu.2013.80. Epub 2013 Mar 14. PMID: 23486531.

Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009 Feb 5;113(6):1315-25. doi: 10.1182/blood-2008-06-163246. Epub 2008 Oct 2. PMID: 18832655; PMCID: PMC2637194.

Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One. 2007 Nov 21;2(11):e1225. doi: 10.1371/journal.pone.0001225. PMID: 18030353; PMCID: PMC2075364.

McIver Z, Serio B, Dunbar A, O'Keefe CL, Powers J, Wlodarski M, Jin T, Sobecks R, Bolwell B, Maciejewski JP. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2008 Apr;141(2):170-8. doi: 10.1111/j.1365-2141.2008.07021.x. Epub 2008 Mar 3. PMID: 18318770.

Kirsten JH, Xiong Y, Dunbar AJ, Rai M, Singleton CK. Ammonium transporter C of Dictyostelium discoideum is required for correct prestalk gene expression and for regulating the choice between slug migration and culmination. Dev Biol. 2005 Nov 1;287(1):146-56. doi: 10.1016/j.ydbio.2005.08.043. Epub 2005 Sep 26. PMID: 16188250.

Review articles, chapters, editorials, etc:

Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020 Jul 2;136(1):61-70. doi: 10.1182/blood.2019000943. PMID: 32430500; PMCID: PMC7332899.

Dunbar A, Nazir A, Levine R. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr Protoc Pharmacol. 2017 Jun 22;77:14.40.1-14.40.19. doi: 10.1002/cpph.23. PMID: 28640953; PMCID: PMC6352313.

Dunbar A, Levine RL. "Interferon" with MPN hematopoietic stem cells. Blood. 2021 Apr 22;137(16):2129-2130. doi: 10.1182/blood.2021011273. PMID: 33885710.

Dunbar A, Park Y, Levine R. Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 Apr;35(2):237-251. doi: 10.1016/j.hoc.2021.01.001. Epub 2021 Feb 5. PMID: 33641866; PMCID: PMC7927771.

Dunbar A, Gotsis W, Frishman W. Second-hand tobacco smoke and cardiovascular disease risk: an epidemiological review. Cardiol Rev. 2013 Mar-Apr;21(2):94-100. doi: 10.1097/CRD.0b013e31827362e4. PMID: 22968181.

Dunbar A, Tallman M. Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia. The ASCO Post. 5/2018.

Dunbar AJ and Berman E. (2018). Chronic Myelogenous Leukemia. In N. Vasan and M.I. Carlo (Eds.), Pocket Oncology (2nd ed., New York: Wolters Kluwer).